Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, and Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved a new dosing regimen for Pennsaid(R) (topical diclofenac). Paladin sells and markets Pennsaid in Canada, having acquired exclusive Canadian Pennsaid rights from Nuvo in August 2005.
The new dosing regimen of Pennsaid(R) will be 50 drops per knee, 3 times a day, as an alternative to the existing approved dosing regimen of 40 drops per knee, 4 times a day. Pennsaid(R) is now the only topical NSAID approved in Canada with this new improved dosing regimen. Pennsaid had Canadian sales of $10.6 million last year and has been sold in Canada since May 2003.
The whole story can be read here.
No comments:
Post a Comment